fbpx Skip to main content
 

Search

Janssen Search

Search results

256 SEARCH RESULTS FOR

faxtor 11 phase 3

Not finding what you're looking for? Visit Janssen in your country.
PAGE 21 OF 26

Pages

Janssen Stands United with Patients on World IBD Day 2018   On May 19, we recognize World Inflammatory Bowel Disease (IBD) Day at Janssen by shedding light on the more than five million people around the world affected by Crohn’s disease and ulcerative ...

Article Block Text:  Intercepting the progression of presbyopia and cataracts. Article Type:  Disease Interception Accelerator Presbyopia and Cataracts Working to develop topical solutions (eye drops) that will intercept presbyopia and cataracts and ...

May 28, 2024 The Company 1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary 2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in ...

Article Block Text:  We are honored to receive awards and recognition for our work and community contributions around the world. Article Type:  Explore We are honored to receive awards and recognition for our work and community contributions around the ...

HUSSEINI K. MANJI, M.D., FRCPC GLOBAL THERAPEUTIC AREA HEAD NEUROSCIENCE Husseini K. Manji, M.D., FRCPC is Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Johnson & Johnson pharmaceutical companies. He ...

Recognizing World IBD Day 2017   Today, May 19 th, and every day, our focus at Janssen Immunology remains on advancing the science and understanding of Inflammatory Bowel Disease (IBD) with patients at the forefront. As a gastroenterologist who practiced ...

Progress, Patients & Passion: Reflections on World Cancer Day 2019   A little over a decade ago, February 4 was declared World Cancer Day in an effort to raise awareness and education of cancer, and encourage a global unified fight against the disease ...

Welcome to the Janssen Oncology ASCO Newsroom I have the pleasure of leading a talented global team of scientists and professionals focused on a lofty yet achievable vision — the elimination of cancer. Our work spans end-to-end oncology research and ...

Article Type:  Other Janssen Clinical Innovation Challenge: Transforming (Long-Term Extension) Studies Janssen Clinical Innovation (JCI) is a team within Janssen Research & Development, LLC, leading efforts to develop and implement new approaches to ...

Nov 14, 2023 United States Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO ® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen ...

256 SEARCH RESULTS FOR

faxtor 11 phase 3

Not finding what you're looking for? Visit Janssen in your country.
PAGE 21 OF 26

Pages